Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates

H H Backus1, H M Pinedo, D Wouters

  • 1Department of Medical Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands.

Oncology Research
|June 22, 2001
PubMed

Insights

Differences in how chemotherapy drugs like 5-fluorouracil (5-FU) and antifolates affect thymidylate synthase (TS) inhibition lead to distinct downstream effects in colon cancer cells. These variations stem from additional drug actions beyond TS inhibition.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Thymidylate synthase (TS) is a key target in chemotherapy.
  • 5-fluorouracil (5-FU), AG337 (Nolatrexed), and multitargeted antifolate (MTA/Pemetrexed) inhibit TS.
  • 5-FU and MTA have additional mechanisms of action beyond TS inhibition.

Purpose of the Study:

  • To investigate downstream effects of TS inhibitors in human colon cancer cells.
  • To compare DNA damage, cell cycle arrest, protein expression, and cell death induced by 5-FU, AG337, and MTA.
  • To elucidate the impact of drug-specific actions on cellular responses.

Main Methods:

  • Treatment of WiDr and Lovo colon cancer cell lines with equitoxic drug concentrations.
  • Assessment of DNA damage.
  • Flow cytometry (FACS) for cell cycle analysis.
  • Western blotting for protein expression (p53, bcl-2/bax ratio).

Main Results:

  • AG337 induced more DNA damage than MTA and 5-FU.
  • All drugs caused S phase arrest, most pronounced with 5-FU and AG337.
  • p53 induction timing varied based on drug and cell line p53 status.
  • Antifolates decreased the bcl-2/bax ratio, unlike 5-FU.
  • Similar levels of cell death were observed across treatments.

Conclusions:

  • Downstream events differ between AG337 and 5-FU/MTA due to non-TS inhibitory actions of 5-FU and MTA.
  • Drug-specific mechanisms, beyond TS inhibition, influence cellular responses in colon cancer.
  • Understanding these distinct pathways is crucial for optimizing chemotherapy strategies.

Related Concept Videos

DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...